Apimeds Pharmaceuticals US
APUSApimeds Pharmaceuticals US, Inc. is a diversified holding company operating through two distinct business lines: clinical-stage biopharmaceutical development and institutional digital asset treasury solutions.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Apimeds Pharmaceuticals US, Inc. is a diversified holding company operating through two distinct business lines: clinical-stage biopharmaceutical development and institutional digital asset treasury solutions. The company focuses on developing bee venom-based toxins for inflammatory conditions while simultaneously providing infrastructure for corporations to manage and generate yield on Bitcoin reserves.
The company holds a unique dual-sector position, leveraging licensed clinical data from South Korea for its biotech arm and a Bitcoin-centric reserve strategy for its fintech platform.
FAQ
- What is Apimeds Pharmaceuticals US's market cap?
- Apimeds Pharmaceuticals US (APUS) has a market capitalization of $6.9M and trades on AMEX.
- Who are Apimeds Pharmaceuticals US's competitors?
- Apimeds Pharmaceuticals US's key competitors include MicroStrategy Incorporated, Lite Strategy, Inc. Common Stock, Avalo Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Apimeds Pharmaceuticals US partner with?
- Apimeds Pharmaceuticals US's notable partners include Apimeds Inc. (Korea), Piramal Pharma Solutions, Apico, Inc., and others.
- What subsidiaries does Apimeds Pharmaceuticals US have?
- Apimeds Pharmaceuticals US's subsidiaries include Lokahi Therapeutics, Inc., MindWave Innovations Inc, TechyTrade Innovations Pte. Ltd., and others.
- Where is Apimeds Pharmaceuticals US headquartered?
- Apimeds Pharmaceuticals US is headquartered in United States of America and employs approximately 2 people. It has been publicly traded since 2025.